HK1200720A1 - Etanercept formulations stabilized with combinations of sugars and polyols - Google Patents

Etanercept formulations stabilized with combinations of sugars and polyols

Info

Publication number
HK1200720A1
HK1200720A1 HK15101256.0A HK15101256A HK1200720A1 HK 1200720 A1 HK1200720 A1 HK 1200720A1 HK 15101256 A HK15101256 A HK 15101256A HK 1200720 A1 HK1200720 A1 HK 1200720A1
Authority
HK
Hong Kong
Prior art keywords
polyols
sugars
combinations
etanercept formulations
formulations stabilized
Prior art date
Application number
HK15101256.0A
Other languages
English (en)
Chinese (zh)
Inventor
馬克．曼寧
布萊恩．墨菲
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of HK1200720A1 publication Critical patent/HK1200720A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
HK15101256.0A 2011-10-18 2015-02-05 Etanercept formulations stabilized with combinations of sugars and polyols HK1200720A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060748 WO2013059412A1 (fr) 2011-10-18 2012-10-18 Préparations d'étanercept stabilisées avec des combinaisons de sucres et de polyols

Publications (1)

Publication Number Publication Date
HK1200720A1 true HK1200720A1 (en) 2015-08-14

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
HK15101257.9A HK1200721A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with xylitol
HK15101254.2A HK1200719A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with metal ions
HK15101256.0A HK1200720A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with combinations of sugars and polyols
HK15101258.8A HK1200722A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with meglumine
HK15101253.3A HK1200718A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with sodium chloride
HK15101255.1A HK1200851A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with amino acids

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK15101257.9A HK1200721A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with xylitol
HK15101254.2A HK1200719A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with metal ions

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK15101258.8A HK1200722A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with meglumine
HK15101253.3A HK1200718A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with sodium chloride
HK15101255.1A HK1200851A1 (en) 2011-10-18 2015-02-05 Etanercept formulations stabilized with amino acids

Country Status (27)

Country Link
US (21) US9302002B2 (fr)
EP (6) EP2768531A4 (fr)
JP (6) JP6220789B2 (fr)
KR (7) KR20140083037A (fr)
CN (6) CN104010657A (fr)
AR (6) AR088383A1 (fr)
AU (6) AU2012326084B2 (fr)
BR (6) BR112014009031A2 (fr)
CA (6) CA2851628A1 (fr)
CY (1) CY1121843T1 (fr)
DK (1) DK2768525T3 (fr)
EA (6) EA026410B1 (fr)
ES (1) ES2734070T3 (fr)
HK (6) HK1200721A1 (fr)
HR (1) HRP20191215T1 (fr)
HU (1) HUE045624T2 (fr)
IL (6) IL231828A0 (fr)
IN (3) IN2014CN02592A (fr)
LT (1) LT2768525T (fr)
MX (7) MX367054B (fr)
PL (1) PL2768525T3 (fr)
PT (1) PT2768525T (fr)
RS (1) RS59179B1 (fr)
SG (6) SG11201401517VA (fr)
SI (1) SI2768525T1 (fr)
TW (6) TWI595883B (fr)
WO (6) WO2013059406A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
BR112014009031A2 (pt) * 2011-10-18 2017-05-09 Coherus Biosciences Inc formulações de etanercept estabilizadas com íons de metais
JP6271536B2 (ja) * 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
CN110051823A (zh) 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
CN105873601A (zh) * 2013-05-02 2016-08-17 马柏克辛斯公司 TNFR:Fc融合多肽的替代配方
WO2015056613A1 (fr) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Préparation aqueuse de polypeptide stabilisée
SG11201603206UA (en) * 2013-10-24 2016-05-30 Medimmune Llc Stable, aqueous antibody formulations
EP3073992A4 (fr) * 2013-11-29 2017-09-13 Ares Trading S.A. Formulation liquide d'une protéine de fusion comprenant le tnfr et une région fc
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (fr) 2014-06-20 2015-12-23 Reform Biologics, Llc Composés excipient réduisant la viscosité pour formulations à base de protéines
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
EP3236990B1 (fr) * 2014-12-22 2020-09-02 Ares Trading S.A. Composition pharmaceutique liquide
WO2016103034A1 (fr) * 2014-12-23 2016-06-30 Drug Discovery Laboratory As Compositions de protéines et leur utilisation
MX2017008633A (es) * 2014-12-31 2018-04-26 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (fr) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Composition pharmaceutique contenant de la micafungine dans un état stabilisé
US20180110856A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
WO2018080196A2 (fr) * 2016-10-28 2018-05-03 (주)셀트리온 Formulation pharmaceutique stable
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
CN109350740B (zh) * 2017-11-30 2023-06-20 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
JP2021508687A (ja) * 2017-12-22 2021-03-11 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2023502777A (ja) * 2019-11-26 2023-01-25 コメラ ライフ サイエンシズ，インコーポレイテッド バイオポリマー製剤のための賦形剤化合物
AU2022223669A1 (en) 2021-02-17 2023-08-03 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
WO1994006476A1 (fr) 1992-09-15 1994-03-31 Immunex Corporation Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000062790A2 (fr) 1999-04-19 2000-10-26 Immunex Corporation Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
WO2001058473A1 (fr) 2000-02-10 2001-08-16 Wyeth Procede destine a traiter ou a inhiber des lesions ou des morts cellulaires
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
SI1946776T1 (sl) * 2002-02-27 2017-07-31 Immunex Corporation Stabiliziran tnfr-fc sestavek, ki obsega arginin
DE602004013557D1 (de) * 2003-02-28 2008-06-19 Ares Trading Sa FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
RU2006101216A (ru) 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
BRPI0415373A (pt) 2003-10-14 2006-12-12 Intermune Inc ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
EP2540815A1 (fr) 2004-03-05 2013-01-02 DSM IP Assets B.V. Culture de cellules par perfusion continue
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
AU2006256041B2 (en) * 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
ES2776657T3 (es) * 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
CA2634131C (fr) * 2005-12-21 2014-02-11 Wyeth Formulations de proteines a viscosite reduite et leurs utilisations
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
NZ591252A (en) * 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
EP1996076A2 (fr) 2006-03-21 2008-12-03 Eugen Oetringer Dispositifs et procédés d'analyse d'une condition physiologique d'un sujet physiologique basée sur une propriété associée de charge de travail
CA2649538C (fr) 2006-04-21 2014-06-03 Yatin Gokarn Agents de tamponnage pour formulations biopharmaceutiques
CN103540575A (zh) * 2006-08-01 2014-01-29 奇尼塔二有限责任公司 医药制造方法
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
MX2009006594A (es) 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
EP2924113B1 (fr) 2007-03-02 2019-04-10 Wyeth LLC Utilisation de cuivre et de glutamate dans la culture de cellules pour la production de polypeptides
EP2014760A1 (fr) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S Méthode pour produire un biopolymère (e.g. un polypeptide) pendant un procédé de fermentation continue
EP2170390B1 (fr) 2007-06-14 2018-11-07 Biogen MA Inc. Formulations d'anticorps natalizumab
SG10201604258YA (en) 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
CN104188911A (zh) * 2008-01-15 2014-12-10 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
EP2260054B1 (fr) 2008-02-29 2015-06-03 Biogen Idec MA Inc. Protéines hybrides purifiées d immunoglobuline et leurs procédés de purification
WO2011015926A1 (fr) 2009-08-03 2011-02-10 Avesthagen Limited Procédé de fermentation, de purification et de production d’une protéine hybride soluble de recombinaison du récepteur du facteur de nécrose tumorale alpha (tnfr) - domaine fc de l’igg humaine
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
EP2490780A4 (fr) 2009-10-20 2014-04-09 Merck Sharp & Dohme Utilisation de la chromatographie en mode mixte pour la capture et la purification de produits d'anticorps de base
EP2516467A2 (fr) * 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprenant des antagonistes de tnf-alpha et il-6 et leurs procédés d'utilisation
US9428727B2 (en) 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
EP2598167B1 (fr) * 2010-07-30 2015-04-01 Arecor Limited Compositions aqueuses stabilisées d'anticorps
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
SG189872A1 (en) 2010-10-11 2013-06-28 Abbvie Inc Processes for purification of proteins
RU2614257C2 (ru) 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US20140142055A1 (en) 2011-06-29 2014-05-22 Insite Vision Corporation Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
ES2625045T3 (es) 2011-07-01 2017-07-18 Amgen Inc. Cultivo de células de mamífero
DK2726090T3 (da) 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
ES2651483T3 (es) 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
BR112014009031A2 (pt) * 2011-10-18 2017-05-09 Coherus Biosciences Inc formulações de etanercept estabilizadas com íons de metais
CN110051823A (zh) 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普

Also Published As

Publication number Publication date
MX2014004732A (es) 2015-05-15
CA2851639A1 (fr) 2013-04-25
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (fr) 2013-04-25
TW201325609A (zh) 2013-07-01
AR088382A1 (es) 2014-05-28
MX2014004726A (es) 2015-05-15
JP2014530255A (ja) 2014-11-17
US20190216930A1 (en) 2019-07-18
ES2734070T3 (es) 2019-12-04
CA2851651A1 (fr) 2013-04-25
EP2768854A1 (fr) 2014-08-27
US20190290768A1 (en) 2019-09-26
US20190290765A1 (en) 2019-09-26
JP6220789B2 (ja) 2017-10-25
JP2014530863A (ja) 2014-11-20
US9943601B2 (en) 2018-04-17
WO2013059412A1 (fr) 2013-04-25
EP2768531A1 (fr) 2014-08-27
EA027325B1 (ru) 2017-07-31
HK1200722A1 (en) 2015-08-14
MX2014004733A (es) 2015-05-15
US20160199489A1 (en) 2016-07-14
IL231828A0 (en) 2014-05-28
US10980885B2 (en) 2021-04-20
TW201325611A (zh) 2013-07-01
EA201490802A1 (ru) 2014-08-29
CA2851646A1 (fr) 2013-04-25
HK1200718A1 (en) 2015-08-14
IL231827A0 (en) 2014-05-28
JP6199298B2 (ja) 2017-09-20
AU2012326082B2 (en) 2016-12-15
MX2014004725A (es) 2015-02-05
AU2012326080A1 (en) 2014-04-24
AU2012326080B2 (en) 2017-02-16
US20160317667A1 (en) 2016-11-03
CN103998061A (zh) 2014-08-20
PL2768525T3 (pl) 2019-10-31
MX2014004734A (es) 2015-05-15
EP2768531A4 (fr) 2015-03-11
HK1200721A1 (en) 2015-08-14
BR112014009146A2 (pt) 2017-06-13
CA2851635A1 (fr) 2013-04-25
EP2768533A4 (fr) 2015-03-11
KR20140079491A (ko) 2014-06-26
SG11201401562RA (en) 2014-09-26
DK2768525T3 (da) 2019-07-22
BR112014009073A2 (pt) 2017-05-09
US20200405865A1 (en) 2020-12-31
JP2014530862A (ja) 2014-11-20
US10987405B2 (en) 2021-04-27
EA201490803A1 (ru) 2014-09-30
AR088460A1 (es) 2014-06-11
US20130101584A1 (en) 2013-04-25
SG11201401563SA (en) 2014-09-26
US9770510B2 (en) 2017-09-26
CA2851639C (fr) 2020-12-29
JP6113176B2 (ja) 2017-04-12
EA201490804A1 (ru) 2014-09-30
EP2768532A4 (fr) 2015-03-11
JP2014530254A (ja) 2014-11-17
CN103998060B (zh) 2016-12-21
JP2014530256A (ja) 2014-11-17
EP2768525A4 (fr) 2015-07-15
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (fr) 2015-06-26
SG11201401567YA (en) 2014-07-30
HUE045624T2 (hu) 2020-01-28
US20130108632A1 (en) 2013-05-02
BR112014009031A2 (pt) 2017-05-09
US10980884B2 (en) 2021-04-20
WO2013059406A1 (fr) 2013-04-25
JP2014530864A (ja) 2014-11-20
BR112014009087A2 (pt) 2017-04-18
SG11201401517VA (en) 2014-09-26
BR112014009131A8 (pt) 2017-06-20
US20190314500A1 (en) 2019-10-17
US20180125982A1 (en) 2018-05-10
US20180193463A1 (en) 2018-07-12
IN2014CN02592A (fr) 2015-09-04
PT2768525T (pt) 2019-07-17
US20130101640A1 (en) 2013-04-25
CN104010654A (zh) 2014-08-27
SI2768525T1 (sl) 2019-10-30
IL231826A0 (en) 2014-05-28
AU2012326084B2 (en) 2016-12-15
TWI644681B (zh) 2018-12-21
US20190314498A1 (en) 2019-10-17
TW201325606A (zh) 2013-07-01
CN104011073B (zh) 2017-08-25
KR20200008021A (ko) 2020-01-22
AR088380A1 (es) 2014-05-28
HK1200851A1 (en) 2015-08-14
CN103998060A (zh) 2014-08-20
JP6110393B2 (ja) 2017-04-05
RS59179B1 (sr) 2019-10-31
SG11201401576WA (en) 2014-10-30
US20130108633A1 (en) 2013-05-02
WO2013059408A1 (fr) 2013-04-25
IL231824A0 (en) 2014-05-28
US10772963B2 (en) 2020-09-15
US20180028668A1 (en) 2018-02-01
KR102068462B1 (ko) 2020-01-22
MX2019009176A (es) 2019-10-07
AR088381A1 (es) 2014-05-28
EP2768525A1 (fr) 2014-08-27
CN104010658A (zh) 2014-08-27
EA201490801A1 (ru) 2014-09-30
MX367054B (es) 2019-08-02
MX2014004728A (es) 2015-05-15
AU2012326084A1 (en) 2014-04-17
US11135267B2 (en) 2021-10-05
BR112014009131A2 (pt) 2017-06-13
AR088383A1 (es) 2014-05-28
IL231829A0 (en) 2014-05-28
US11129876B2 (en) 2021-09-28
AU2012326171A1 (en) 2014-04-24
JP6104922B2 (ja) 2017-03-29
IN2014CN02527A (fr) 2015-06-26
WO2013059410A1 (fr) 2013-04-25
US20190290767A1 (en) 2019-09-26
KR20140091706A (ko) 2014-07-22
TW201325608A (zh) 2013-07-01
KR20140091707A (ko) 2014-07-22
EP2768535A4 (fr) 2015-03-11
CN104010654B (zh) 2017-10-27
TW201325610A (zh) 2013-07-01
BR112014009146A8 (pt) 2017-06-20
CA2851628A1 (fr) 2013-04-25
EA025267B1 (ru) 2016-12-30
US20190314499A1 (en) 2019-10-17
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
CA2851642A1 (fr) 2013-04-25
US9801942B2 (en) 2017-10-31
US9302002B2 (en) 2016-04-05
AU2012326171B2 (en) 2017-03-09
KR20140091705A (ko) 2014-07-22
AU2012326082A1 (en) 2014-04-24
TWI595883B (zh) 2017-08-21
US20190298837A1 (en) 2019-10-03
SG11201401519RA (en) 2014-07-30
AU2012326170B2 (en) 2016-12-22
TWI619504B (zh) 2018-04-01
EA026410B1 (ru) 2017-04-28
US20190184017A1 (en) 2019-06-20
HRP20191215T1 (hr) 2019-10-04
KR20140083037A (ko) 2014-07-03
EP2768533A1 (fr) 2014-08-27
TW201325607A (zh) 2013-07-01
AU2012326168B2 (en) 2016-12-15
KR20140097184A (ko) 2014-08-06
EA025663B1 (ru) 2017-01-30
KR102163150B1 (ko) 2020-10-08
CY1121843T1 (el) 2020-07-31
AR088379A1 (es) 2014-05-28
US10376588B2 (en) 2019-08-13
AU2012326170A1 (en) 2014-04-24
IL231825A0 (en) 2014-05-28
US20190290766A1 (en) 2019-09-26
JP6220788B2 (ja) 2017-10-25
EP2768525B1 (fr) 2019-06-19
LT2768525T (lt) 2019-09-25
EA201490815A1 (ru) 2014-09-30
BR112014009022A2 (pt) 2017-05-02
US10888619B2 (en) 2021-01-12
EP2768535A1 (fr) 2014-08-27
CN104010657A (zh) 2014-08-27
WO2013059407A1 (fr) 2013-04-25
US10213508B2 (en) 2019-02-26
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
EP2768532A1 (fr) 2014-08-27
AU2012326168A1 (en) 2014-04-24
EP2768854A4 (fr) 2015-03-11
EA201490817A1 (ru) 2014-09-30

Similar Documents

Publication Publication Date Title
HK1200720A1 (en) Etanercept formulations stabilized with combinations of sugars and polyols
ZA201608660B (en) Anti - sclerostin antibody crystals and formulations thereof
IL229629B (en) Synthetic formulations and methods for their production and use
EP2721019A4 (fr) Compositions thérapeutiquement actives et leurs procédés d'utilisation
GB2507210B (en) Insecticidal compositions and methods of using the same
ZA201402734B (en) Collector compositions and methods of using the same
EP2709694A4 (fr) Injecteur à usage unique peu coûteux
EP2763541A4 (fr) Formulations de lutte contre les nuisibles et leurs procédés de fabrication et d'utilisation
EP2798058A4 (fr) Méthodes et compositions permettant l'obtention, à des fins cliniques, d'une cellule allogène et ses utilisations thérapeutiques
EP2753337A4 (fr) Compositions comprenant des bêta-glucanes et leurs procédés d'utilisation
EP2706845A4 (fr) Matériau solide antimicrobien et ses procédés de fabrication et d'utilisation
EP2708230A4 (fr) Composition pour utilisation externe sur la peau pour des maladies inflammatoires
IL231490A0 (en) Preparations and methods for the production and use of human cholinesterases
HUE037704T2 (hu) Herbicid kompozíció, és eljárás annak alkalmazására
ZA201403717B (en) Compositions and methods for increased expression in sugar cane
TWM433230U (en) Improved structure of chessboard
GB201113314D0 (en) Formulations and processes

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211016